The group’s 7-2 ruling in favor of the therapeutic represents a shift from previous deliberations, in which data on its effectiveness was deemed insufficient.

The Scientist spoke to Mount Desert Island Biological Laboratory’s Jim Strickland about the institute’s new MDI Bioscience initiative to perform more drug testing and development in nonmammalian models.

A first-of-its-kind gene therapy dramatically reduced misfolded protein levels in some clinical trial participants for up to six months and reduced levels in all participants for up to a year.

Authors of papers published in JAMA and NEJM received millions in undisclosed payments in 2017, an analysis finds.

The cardiologist was briefly the FDA Commissioner in the Obama Administration, and now has a second chance to act on plans he tried to implement during his first tenure.

Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

The recent move of the European Medicines Agency from London to Amsterdam is a reflection of the city’s vibrant life sciences and health sector and supporting industries.

There are benefits of studying certain biological processes under microgravity, but whether those advantages outweigh the costs of getting experiments off Earth remains to be seen.

Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.

Officials had initially linked 97 cases to a single conference held by Biogen in February in Boston, but a new study tracking viral genomes suggests the number may be as high as 20,000.

Citizen advocates push the pharmaceutical company to examine a compound that has been used to treat certain coronavirus infections in cats.

Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.

The urgent need for tests and therapeutics has brought companies together and pushed researchers to work at breakneck speeds.

The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.

The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.

The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.

Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.

The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.